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Medical Cannabis Treatments
Abstract
This research report examines past research studies on marijuana therapy
interventions involving individuals who have Autism Spectrum Disorder,
Epilepsy, and Tourette’s Syndrome. These results do not ensure marijuana
as a permanent method to cure adverse symptoms for these vulnerable
populations. However, these large-scale studies have shown a trend of
marijuana being effective for some participants involved in decreasing
and/or improving their symptom frequency. This report will contribute to
the knowledge pool on the safety and effectiveness of marijuana therapy.
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Introduction
Many research studies have investigated the effects of medical
marijuana on patients with neurobehavioral disorders. Other areas of
medical marijuana treatment are used in patients with chronic pain,
depression, and cancer. This literature review will be focusing on the results
of the therapy interventions for patients with Autism Spectrum Disorder
(ASD), Epilepsy, and Tourette’s Syndrome. Marijuana treatment can
improve the quality of life for these patients who struggle with
uncontrollable impulsive behavior, anxiety, self-injury, aggressiveness, and
seizures. Unfortunately, since marijuana is classified as a schedule 1 drug
under the federal government, it is looked down upon as a form of medical
treatment.
Medical Marijuana Effects on Autism Spectrum Disorder
Autism Spectrum Disorder (ASD) is a form of neurodivergence that
is still insufficiently understood. Research studies have investigated the
effects of medical marijuana on ASD patients. These studies will be
comparing two studies and the results they find on the safety and utilization
of marijuana on ASD patients. The terms discussed in this paper are the
components of marijuana which are cannabidiol (CBD) and Δ9tetrahydrocannabinol (THC). THC is known for its psychoactive effects
directly affecting the central nervous system (Agarwal et al., 2019). THC
affects things like appetite and cognitive function. In comparison, CBD is
an anti-inflammatory component used to treat epilepsy and psychiatric
disorders without the psychoactive effects (Agarwal et al.).
Schleider et al. (2019) collected data from 188 individuals on the
ASD spectrum undergoing a cannabis treatment program. This study aimed
to track the patient population receiving medical cannabis treatment and
evaluate the therapy’s safety (Schleider et al.). Subjects diagnosed with
ASD ranging from ages under five to 18 years old were given cannabis oil
to consume 3x a day orally (Schleider et al.). Most patients consumed oil
containing 30% CBD and 1.5% THC (Schleider et al.). Researchers then
gathered data from the study population in three follow-up periods
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immediately after in-take, one month, and six months to see what changed
between the patients.
The study results indicated that a majority of the patients reported a
better quality of life and a positive mood change after treatment (Schleider
et al., 2019). Based on these results, we can conclude that the use of
cannabis is, in fact, safe and well-tolerated. Schleider et al. stated that
“patients who reported side effects of the treatment were moderate and easy
to cope with.” Roughly 80% of the ASD research participants reported a
significant/moderate behavior improvement.
Agarwal et al. (2019) reported a different study that collected data
from 53 children diagnosed with ASD. These 53 children were prescribed
oral cannabinoids that contained 16mg of CBD and 0.8mg of THC per
serving (Agarwal et al.). The purpose of this study was to track the patient’s
symptoms using bi-weekly interviews with parents (Agarwal et al., 2019).
Patients before this study would deal with symptoms such as hyperactivity,
sleep problems, and anxiety (Agarwal et al.). Data was collected based on
the children’s symptoms and how they were affected by the cannabinoids,
described as improvement, no change, or worsening (Agarwal et al.).
Agarwal et al. (2019) reported that 74.5% of the participants
experienced an improvement in ASD comorbidity symptoms. Similarly,
Schleider et al. (2019) reported even higher results being 80% significant
improvement in behavior. Based on the results of Agarwal et al. and
Schleider et al. studies, it can be concluded that oral medical marijuana
treatment is a potentially safe method to improve patients’ symptoms of
ASD. However, the studies’ similar limitations were that they lacked a
control group. In the Schleider et al. study, the limitation was an
observational study with no control group. Therefore, no causality between
the cannabis treatment and improvement in patients’ wellbeing can be
concluded (Schleider et al.). Agarwal et al. had the exact problem of having
no control group and objective assessment tools. Therefore, we cannot
conclude that medical marijuana was the reason for the improved
symptoms. Still, it is a safe treatment due to the mild side effects reported
from each study. Another limitation that both studies had was that they
gathered information from the patient’s family and not from the patient
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themselves. Some ASD patients could not vouch for themselves on how the
treatment made them feel.
In conclusion, more evidence is needed to ensure that medical
marijuana effectively treats ASD patients. Marijuana or any drug has not
been discovered to cure the symptoms of ASD permanently. However,
large-scale studies like the ones discussed in this review help build our
knowledge of the safety and effects of cannabis on patients who have ASD.
Future research on medical marijuana therapy for ASD patients could
include control groups. More research under control groups can help
researchers create a cause-and-effect relationship between marijuana and
ASD symptoms.
Ethical Implications
Many families seek alternate treatment methods for their children
with ASD (Duvall S et al. 2019). Complementary Health Approaches
(CHAs) offers an array of health approaches outside mainstream medicine
to treat core symptoms for ASD. Cannabis has been considered a potential
CHA treatment method to help reduce severe ASD symptoms. Cannabis is
legal in 33 states, while recreational marijuana is legal in 10 states. Oregon,
for example, does not allow recreational use for anyone under 21 but has no
age limit for medical use. Many may argue that giving pediatric patients
marijuana is unethical, but there can be a new opportunity to accept this
treatment by following regulations. The ethical criteria researchers should
have their participants meet before they participate in marijuana therapy is
to have a statement that verifies the diagnosis of their medical condition and
certifies that the use of cannabis may migrate their symptoms (Duvall S et
al.). The participants also must have a designated caregiver responsible for
providing supervision while the therapy is ongoing (Duvall S et al.). If these
criteria are followed, and studies that support that marijuana therapy reduce
self-harm in patients with ASD, it would be considered unethical for a
clinician to be against its use (Duvall S et al.)
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Medical Marijuana effects on Tourette’s Syndrome
Tourette’s Syndrome (TS) is an inherited psychiatric symptom that
involves involuntary motor and vocal tics that stay persistent for longer than
one year (Abi-Jaoude et al., 2017). TS in some patients may involve other
comorbidity symptoms such as obsessive-compulsive disorder (OCD),
attention deficit hyperactivity disorder (ADHD), and rage attack (AbiJaoude et al.). Below are discussed studies that have been conducted on the
effects of marijuana therapy on patients with TS.
Abi-Jaoude et al. (2017) conducted semi-structured interviews on
the effects cannabis had on the patient’s symptomatology of tics and
comorbidities. 21/19 of the participants were willing to take part in the
interview process. Abi-Jaoude et al. found that all 19 patients reported
improving comorbid symptoms with cannabis, such as rage outbursts, sleep,
attention, irritability, and obsessive-compulsive symptoms. Further results
also showed that 18/19 patients decreased total tic severity (Abi-Jaoude et
al.). Similarly, Müller-Vahl (2013) performed a survey on the use of
Cannabis Sativa and its effects on patients with Tourette’s Syndromes and
other psychiatric comorbidities, including motor vocal tics, obsessive and
compulsive behavior, and ADHD (Müller-Vahl ). Over 80% reported that
their symptoms were improved or resolved (Müller-Vahl). None of these
patients had reported any adverse effects during the duration of their
cannabis use (Müller-Vahl pg, 120).
Hemming & Yellowlees (1993) report a single subject case
involving a 36-year-old man named Mr. A who discovered an effective
treatment for his Tourettes Syndrome. Mr. A began smoking a regular dose
of a “cone” per night (Hemming & Yellowlees). Within a week, the results
showed that “he was completely symptom-free, much to his surprise and
delight” (Hemming & Yellowlees, pg. 390). Similar to Hemming &
Yellowlees (1993), Sandyk (1988) reported the results of marijuana therapy
in male patients ages 15, 17, and 39 years old who all have Tourette’s
Syndrome. The first patient was a 15-year-old boy who smoked 1-2
marijuana joints daily (Sandyk). His mother reported a 50% decrease in his
tic symptoms (Sandyk). The second patient is 17 years old and was
diagnosed with Tourette's Syndrome at age seven (Sandyk). His symptoms
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include frequent jerk movements of his neck muscles, infrequent
vocalizations, and anxiety (Sandyk). After using recreational marijuana, his
relaxation levels had increased while his tics decreased by 70% (Sandyk).
Lastly, we have a 39-year-old patient diagnosed with Tourette's Syndrome
at age nine (Sandyk). His symptoms included neck and leg jerking, blinking,
chronic insomnia, and hypersexuality (Sandyk). He admitted that smoking
1-½ marijuana joints a day reduces his hypersexuality and motor tics
(Sandyk).
In conclusion, medical cannabis can be a promising treatment for
patients who suffer from TS. Like the ASD studies, these experiments still
need better characterization of the roles of cannabis compounds on TS
patients through more well-controlled studies (Abi-Jaoude et al., 2017).
Medical Marijuana effects on Epilepsy
Around three million people in the United States are diagnosed with
epilepsy, and ⅓ of these patients report poorly controlled seizures
(Kolikonda et al.,2016). Many of these patients suffer through their
symptoms with a decrease in their quality of life. Therefore, marijuana
therapy is introduced to children and adults with different epilepsy
disorders. The anti-inflammatory component of marijuana known as CBD
has impacted seizure symptoms for patients.
Maa and Figi (2014) reported a medical marijuana research study on
a pediatric patient named Charlotte diagnosed with Dravet syndrome.
Dravet syndrome is drug-resistant epilepsy that is lifelong, presenting
prolonged seizures that affect one side of the body (Joshi & Wirell, 2020).
After treating the cannabidiol/Δ9-tetrahydrocannabinol (CBD: THC) strain
of cannabis, Charlotte experienced a decrease in seizures from 50 per day
to 2-3 per month (Maa &Figi). Further pediatric studies such as Dimah
(2014) also found that symptoms of seizures were diminishing in response
to CBD treatment. Dimah conducted a study upon a 10-month-old patient
receiving treatment involving the non-psychoactive part of marijuana
known as CBD to minimize his seizures. Dimah found that the infant
demonstrated developmental gains and seizure reduction in response to the
CBD treatment.
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Kolikonda et al. (2016) reported a survey that 24% of epilepsy
patients admitted utilizing marijuana and claimed it was beneficial to them.
In a pilot study, CBD versus placebo was conducted upon eight normal
volunteers and 15 patients with epilepsy (Kolikonda et al.). These
participants were randomly placed in double-blinded CBD treatment for
phases that lasted between 30-135 days (Kolikonda et al.). Kolikonda et al.
reported that subjects among CBD treatments claimed to be seizure-free,
decreased frequency, or unchanged. Six reported no improvement among
seven placebo-treated individuals, while one claimed better seizure control
(Kolikonda et al.). Like Kolikonda et al., Fong & Kossoff (2018) used
controlled experimental studies to determine the effects of CBD on epilepsy
patients. The Fong & Kossoff study has a few randomized controlled trials
(RCTs) that test the safety and efficacy of CBD on epilepsy patients (Fong
& Kossoff). These had involved trial sites throughout the United States and
Europe, which helped diversify the research patient population (Fong &
Kossoff). Across three RCTs, patients diagnosed with Lennox-Gastaut
syndrome, a severe form of epilepsy, were treated with CBD (Fong &
Kossoff). The results showed that patients reported reduced seizure
frequency or overall symptom-free of seizures (Fong & Kossoff).
Conclusion
This literature review focused on the results of medical marijuana
therapy for patients with ASD, Epilepsy, and Tourettes. More evidence is
needed to ensure that medical marijuana effectively treats patients with
these disorders. Marijuana or any drug has not been discovered to
permanently cure symptoms of patients with ASD, Epilepsy, or Tourette’s.
However, large-scale studies like the ones discussed in this review help
build our knowledge of the safety and effects of cannabis on patients. Future
research involving more control groups can help create a cause-and-effect
relationship between medical marijuana and neurobehavioral symptoms. In
the near future, as more research is conducted, marijuana can be brought
out of the dark light and into a new light as an opportunity to change lives.
When more research is found on marijuana having the potential to be safely
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admitted as a new therapy, then more individuals can be introduced to this
therapy.
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